Английская Википедия:Aimée R. Kreimer

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Infobox scientist

Aimée Rebecca Kreimer (born August 19, 1975) is an American cancer epidemiologist who researches the etiology and prevention of human papillomavirus infection (HPV) and cancer prevention. She is a senior investigator in the infections and immunoepidemiology branch at the National Cancer Institute.

Life

Kreimer was born August 19, 1975, in Washington, D.C.[1] She completed a B.S. in Animal Science with a minor in Biology and a concentration in pre-veterinary medicine at the University of Delaware in May 1997.[1] Kreimer earned a M.S. from the department of health evaluation sciences, division of biostatistics and epidemiology at the University of Virginia in May 1998.[1] Her thesis was titled, Evaluation of the Effectiveness of Treatment with Cortisol in Physiologic Doses in Patients with Naturally Acquired Influenza A.[1] Kreimer received a Ph.D. in infectious disease epidemiology from the Johns Hopkins Bloomberg School of Public Health.[2] Her 2003 dissertation was titled, The descriptive epidemiology of oral human papilloma virus (HPV) infection: associations with high-risk sexual behaviors and HPV serostatus.[1] Anthony J. Alberg was her doctoral advisor and Maura L. Gillison was her mentor.[1] Kreimer conducted postdoctoral research at the International Agency for Research on Cancer and the National Cancer Institute (NCI).[2]

Kreimer is a senior investigator in the NCI infections and immunoepidemiology branch (IIB).[2] She studies the etiology and prevention of human papillomavirus (HPV) and cancers at multiple sites, including the head and neck and anogenital region, with a particular focus on translational research and cancer prevention.[2] In 2018, she received the National Institutes of Health (NIH) Director's Award in the category of Science/Medicine for her outstanding achievements in HPV cancer research and leadership in the Costa Rica HPV Vaccine Trial.[2] In 2021, she was elected by her peers to serve a three-year term as NCI division of cancer epidemiology and genetics (DCEG) Woman Scientific Advisor, and elected to the executive board of the International Papillomavirus Society.[2]

See also

References

Шаблон:Reflist Шаблон:Include-NIH

Шаблон:Authority control